PathoVax is a biotech startup from Johns Hopkins that is commercializing RGVax, a vaccine designed to target and prevent the spread of specific viral infections. The company aims to enhance public health by providing an effective immunization solution that addresses the limitations of current vaccine options.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current vaccines for certain viral infections have limitations in their effectiveness and breadth of protection, leading to continued spread and potential for outbreaks. These limitations can stem from factors such as viral mutation, incomplete immune response, or challenges in vaccine delivery and accessibility.
Solution
PathoVax is developing RGVax, a novel vaccine technology designed to overcome the limitations of existing vaccines and prevent the spread of specific viral infections. The RGVax platform aims to provide a more effective and broadly protective immunization solution. By targeting key viral mechanisms and enhancing the body's immune response, RGVax seeks to improve public health outcomes through superior prevention of viral diseases.
Target Audience
The primary target audience includes public health organizations, healthcare providers, and individuals at risk of contracting specific viral infections.
Features
- Targets specific viral infections with a novel vaccine technology.
- Designed to overcome limitations of current vaccine options.
- Aims to provide a more effective and broadly protective immunization solution.